485 related articles for article (PubMed ID: 23611368)
1. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Steiner S; Panzer S
Eur J Clin Invest; 2013 Jul; 43(7):689-97. PubMed ID: 23611368
[TBL] [Abstract][Full Text] [Related]
2. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.
Gremmel T; Xhelili E; Steiner S; Koppensteiner R; Kopp CW; Panzer S
Atherosclerosis; 2014 Jan; 232(1):119-24. PubMed ID: 24401225
[TBL] [Abstract][Full Text] [Related]
3. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
[TBL] [Abstract][Full Text] [Related]
4. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Transl Res; 2013 May; 161(5):421-9. PubMed ID: 23340049
[TBL] [Abstract][Full Text] [Related]
5. Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel.
Gremmel T; Eslam RB; Koppensteiner R; Lang IM; Panzer S
Cardiovasc Ther; 2013 Oct; 31(5):e40-5. PubMed ID: 23311679
[TBL] [Abstract][Full Text] [Related]
6. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
[TBL] [Abstract][Full Text] [Related]
7. In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Haemost; 2014 Mar; 111(3):474-82. PubMed ID: 24196591
[TBL] [Abstract][Full Text] [Related]
8. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Badr Eslam R; Lang IM; Kaider A; Panzer S
Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
[TBL] [Abstract][Full Text] [Related]
9. The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity.
Gremmel T; Kopp CW; Seidinger D; Giurgea GA; Koppensteiner R; Steiner S; Panzer S
Atherosclerosis; 2009 Dec; 207(2):608-13. PubMed ID: 19616779
[TBL] [Abstract][Full Text] [Related]
10. Calcium-Channel Blockers Attenuate the Antiplatelet Effect of Clopidogrel.
Gremmel T; Durstberger M; Eichelberger B; Koppensteiner R; Panzer S
Cardiovasc Ther; 2015 Oct; 33(5):264-9. PubMed ID: 26014752
[TBL] [Abstract][Full Text] [Related]
11. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
12. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study.
Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
Postgrad Med J; 2006 Jun; 82(968):404-10. PubMed ID: 16754711
[TBL] [Abstract][Full Text] [Related]
13. Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel?
Gremmel T; Calatzis A; Steiner S; Kaider A; Seidinger D; Koppensteiner R; Kopp CW; Panzer S
Platelets; 2010; 21(7):515-21. PubMed ID: 20624009
[TBL] [Abstract][Full Text] [Related]
14. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.
Xiao Z; Théroux P
J Am Coll Cardiol; 2004 Jun; 43(11):1982-8. PubMed ID: 15172401
[TBL] [Abstract][Full Text] [Related]
15. The Antiplatelet Effect of Clopidogrel Decreases With Patient Age.
Xhelili E; Eichelberger B; Kopp CW; Koppensteiner R; Panzer S; Gremmel T
Angiology; 2016 Nov; 67(10):902-908. PubMed ID: 26861857
[TBL] [Abstract][Full Text] [Related]
16. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial.
Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
Int J Clin Pract; 2006 Jul; 60(7):863-6. PubMed ID: 16846403
[TBL] [Abstract][Full Text] [Related]
17. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.
Gremmel T; Koppensteiner R; Panzer S
PLoS One; 2015; 10(6):e0129666. PubMed ID: 26058047
[TBL] [Abstract][Full Text] [Related]
20. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
Klinkhardt U; Bauersachs R; Adams J; Graff J; Lindhoff-Last E; Harder S
Clin Pharmacol Ther; 2003 Mar; 73(3):232-41. PubMed ID: 12621388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
